...
首页> 外文期刊>Cell death & disease. >miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma
【24h】

miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma

机译:通过抑制鼻咽癌的PTEN / AKT途径,MIR-141参与BRD7介导的细胞增殖和肿瘤形成

获取原文
           

摘要

Bromodomain containing 7 (BRD7) was identified as a nuclear transcriptional regulatory factor. BRD7 functions as a tumor suppressor in multiple cancers, including nasopharyngeal carcinoma (NPC). In this study, we reported a novel mechanism of BRD7 in NPC progression. We demonstrated that the expression of miR-141 was remarkably increased in NPC tissues and was negatively correlated with the expression of BRD7 and the survival rate of NPC patients. Decreased expression levels of miR-141, including the primary, the precursor and the mature forms of miR-141, were found in BRD7-overexpressing HEK293, 5-8F and HNE1 cells compared the control cells, while there was no obvious effect on the expression levels of the two critical enzymes Drosha and Dicer. BRD7 can negatively regulate the promoter activity of miR-141, while no obvious binding site of BRD7 was found in the potential promoter region of miR-141. Moreover, ectopic expression of miR-141 can significantly promote cell proliferation and inhibit apoptosis in NPC, and rescuing the expression of miR-141 in BRD7-overexpressing NPC cells could partially reverse the tumor suppressive effect of BRD7 on cell proliferation and tumor growth in vitro and in vivo . Furthermore, the activation of the PTEN/AKT pathway mediated by the overexpression of BRD7 could be inhibited by rescuing the expression of miR-141, which accordingly results in the partial restoration of cell proliferation and tumor growth. Our findings demonstrate that the BRD7/miR-141/PTEN/AKT axis has critical roles in the progression of NPC and provide some promising targets for the diagnosis and treatment of NPC.
机译:含有7(BRD7)的溴酰亚胍蛋白酶被鉴定为核转录调节因子。 BRD7用作多种癌症中的肿瘤抑制剂,包括鼻咽癌(NPC)。在这项研究中,我们报告了NPC进展中BRD7的新机制。我们证明了MiR-141的表达在NPC组织中显着增加,与BRD7的表达和NPC患者的生存率负相关。 MiR-141的表达水平降低,包括MiR-141的初级,前体和成熟形式,在BRD7过表达HEK293,5-8F和HNE1细胞中发现了对照细胞,而对控制细胞没有明显影响两种关键酶Drosha和Dicer的表达水平。 BRD7可以负调节miR-141的启动子活性,而在MiR-141的潜在启动子区中没有发现BRD7的明显结合位点。此外,MIR-141的异位表达可以显着促进NPC中细胞增殖和抑制细胞凋亡,并抵押在BRD7过表达NPC细胞中MIR-141的表达可以部分地逆转BRD7对细胞增殖和体外肿瘤生长的肿瘤抑制作用在体内。此外,通过拯救MiR-141的表达,可以抑制由BRD7的过表达介导的PTEN / AKT途径的活化,这导致细胞增殖和肿瘤生长的部分恢复。我们的研究结果表明,BRD7 / MIR-141 / PTEN / AKT轴在NPC的进展中具有重要作用,并为NPC的诊断和治疗提供了一些有前途的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号